Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H ( (HK:1541) ) has shared an update.
ImmuneOnco Biopharmaceuticals has announced the composition of its board of directors and their roles within the company. This announcement outlines the structure of the board, including executive, non-executive, and independent non-executive directors, as well as the composition of various board committees, which could impact the company’s governance and strategic direction.
More about ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a joint stock company based in China, focusing on biopharmaceuticals. The company operates within the pharmaceutical industry, specializing in the development of innovative cancer immunotherapies.
Average Trading Volume: 4,543,278
Technical Sentiment Signal: Hold
Current Market Cap: HK$8.25B
See more insights into 1541 stock on TipRanks’ Stock Analysis page.